Analytical and Bioanalytical Chemistry

, Volume 398, Issue 7–8, pp 3043–3050 | Cite as

Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure

  • G. de Gennaro
  • S. Dragonieri
  • F. Longobardi
  • M. Musti
  • G. Stallone
  • L. Trizio
  • M. Tutino
Original Paper

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumour whose main aetiology is the long-term exposure to asbestos fibres. The diagnostic procedure of MPM is difficult and often requires invasive approaches; therefore, it is clinically important to find accurate markers for MPM by new noninvasive methods that may facilitate the diagnostic process and identify patients at an earlier stage. In the present study, the exhaled breath of 13 patients with histology-established diagnosis of MPM, 13 subjects with long-term certified professional exposure to asbestos (EXP) and 13 healthy subjects without exposure to asbestos (healthy controls, HC) were analysed. An analytical procedure to determine volatile organic compounds by sampling of air on a bed of solid sorbent and thermal desorption GC-MS analysis was developed in order to identify the compounds capable of discriminating among the three groups. The application of univariate (ANOVA) and multivariate statistical treatments (PCA, DFA and CP-ANN) showed that cyclopentane and cyclohexane were the dominant variables able to discriminate among the three groups. In particular, it was found that cyclohexane is the only compound able to differentiate the MPM group from the other two; therefore, it can be a possible marker of MPM. Cyclopentane is the dominant compound in the discrimination between EXP and the other groups (MPM and HC); then, it can be considered a good indicator for long-term asbestos exposure. This result suggests the need to perform frequent and thorough investigations on people exposed to asbestos in order to constantly monitor their state of health or possibly to study the evolution of disease over time.

Keywords

Biomarkers Malignant pleural mesothelioma Exhaled breath Volatile organic compounds 

References

  1. 1.
    Robinson BW, Lake RA (2005) Advances in previous malignant mesothelioma. N Engl J Med 353(15):1591–1603CrossRefGoogle Scholar
  2. 2.
    Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with previous pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(1):145–152Google Scholar
  3. 3.
    Grellier L, Astoul P (2008) Mesothelioma and asbestos-related plueral diseases. Respiration 76:1–15CrossRefGoogle Scholar
  4. 4.
    Kaufman AJ, Pass HI (2008) Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther 8:293–303CrossRefGoogle Scholar
  5. 5.
    Kent M, Rice D, Flores R (2008) Diagnosis, staging and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 9:158–170CrossRefGoogle Scholar
  6. 6.
    Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A (2008) Biomarkers for malignant pleural mesothelioma. Mol Diagn Ther 12:375–390Google Scholar
  7. 7.
    Pauling L, Robinson AB, Teranishi R, Cary P (1971) Quantitative analysis of urine vapour and breath by gas–liquid partition chromatography. Proc Nat Acad Sci 68:2374–2376CrossRefGoogle Scholar
  8. 8.
    Rooth G, Ostenson S (1966) Acetone in alveolar air and the control of diabetes. Lancet 2:1102–1105CrossRefGoogle Scholar
  9. 9.
    Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O’Neill HJ (1985) Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem 31(8):1278–1282Google Scholar
  10. 10.
    Phillips M (1997) Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 247:272–278CrossRefGoogle Scholar
  11. 11.
    Phillips M, Erickson GA, Sabas M, Smith JP, Greenberg J (1995) Volatile organic compounds in the breath of patients with schizophrenia. J Clin Pathol 48:466–469CrossRefGoogle Scholar
  12. 12.
    Karl T, Prazeller P, Mayr D, Jordan A, Rieder J, Fall R, Lindinger W (2001) Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling. J Appl Physiol 91:762–770Google Scholar
  13. 13.
    Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI (2009) Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 64:744–774CrossRefGoogle Scholar
  14. 14.
    Pleil JD, Lindstrom AB (1997) Exhaled human breath measurement method for assessing exposure to halogenated volatile organic compounds. Clin Chem 43:723–730Google Scholar
  15. 15.
    Amann A, Smith D (2005) Breath analysis for clinical diagnosis and therapeutic monitoring. World Scientific Publishing, 5 Toh Tuck Link, SingaporeGoogle Scholar
  16. 16.
    Belda Iniesta C, de Castro J, Carpeño CJA, Moreno V, Casado Sáenz E, Feliu J, Sereno M, García Río F, Barriuso J, González Barón M (2007) New screening method for lung cancer by detecting volatile organic compounds in breath. Clin Transl Oncol 9:364–368CrossRefGoogle Scholar
  17. 17.
    Friedrich MJ (2009) Scientists seek to sniff out diseases: electronic “noses” may someday be diagnostic tools. JAMA 301:585–586CrossRefGoogle Scholar
  18. 18.
    Sobin LH, Witterkind C (2002) TNM classification of malignant tumours. International Union Against Cancer, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  19. 19.
    Dragonieri S, Schot R, Mertens JA, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, Bel EH, Sterk PJ (2007) An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 120(4):856–862CrossRefGoogle Scholar
  20. 20.
    Bruno P, Caselli M, de Gennaro G, Iacobellis S, Tutino M (2008) Monitoring of volatile organic compounds in non-residential indoor environments. Indoor Air 18:150–156CrossRefGoogle Scholar
  21. 21.
    Zupan J, Gasteiger J (1999) Neural networks in chemistry and drug design, 2nd edn. Wiley-VCH, WeinheimGoogle Scholar
  22. 22.
    Zupan J, Novi M, Ruisánchez I (1997) Kohonen and counterpropagation artificial neural networks in analytical chemistry. Chemom Intell Lab Syst 38:1–23CrossRefGoogle Scholar
  23. 23.
    Kohonen T (1988) Self-organization and associative memory. Springer, BerlinGoogle Scholar
  24. 24.
    Chase RE (2001) Properties and manufacture of TedlarR polyvinyl fluoride film VERL. Ford Research Laboratory ERC Technical Report IssuedGoogle Scholar
  25. 25.
    Steeghs MML, Cristescu SM, Munnik P, Zanen P, Harren FJM (2007) The suitability of Tedlar bags for breath sampling in medical diagnostic research. Physiol Meas 28:73–84CrossRefGoogle Scholar
  26. 26.
    Trabue SL, Anhalt J, Zahn JA (2006) Bias of Tedlar bags in the measurement of agricultural odorants. J Environ Qual 35:1668–1677CrossRefGoogle Scholar
  27. 27.
    Gross P (1984) Biologic activity of epsilon-caprolactam. Crit Rev Toxicol 13:205–216CrossRefGoogle Scholar
  28. 28.
    Landi MT, Consonni D, Rotunno M, Bergen AW, Goldstein AM (2008) Environment and Genetics in Lung Cancer Etiology (EAGLE) Study: an integrative population-based case–control study of lung cancer. BMC Public Health 8:203CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • G. de Gennaro
    • 1
  • S. Dragonieri
    • 2
  • F. Longobardi
    • 1
  • M. Musti
    • 3
  • G. Stallone
    • 1
  • L. Trizio
    • 1
  • M. Tutino
    • 1
  1. 1.Department of ChemistryUniversity of Bari Aldo MoroBariItaly
  2. 2.Department of PulmonologyUniversity of Bari Aldo MoroBariItaly
  3. 3.Department of Occupational MedicineUniversity of Bari Aldo MoroBariItaly

Personalised recommendations